Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Dubinett - Targeted Sequencing 2012

Dubinett - Targeted Sequencing 2012

358

No coordinating investigator defined.

UNKNOWN
Lung and Upper Aerodigestive Cancers Research Group

we propose to use targeted massively parallel DNA sequencing to identify somatic alterations within mutational hotspots in matched sets of primary lung tumors, premalignant lesions, and adjacent,histologically normal lung tissue.

1. Use targeted massively parallel DNA sequencing to assess the presence of mutations in specific genomic regions in matched sets of primary lung adenocarcinomas, premalignant lesions, and adjacent, histologically normal lung tissues obtained from the same patient. What is the prevalence of common lung-cancer-associated mutations in a panel of adenocarcinomas or premalignant lesions from the same patient? What is their baseline prevalence in lung tissue with no histologic indication of disease? 2. To identify mutations whose prevalence is significantly higher in tumors and premalignant lesions than in histologically normal lung tissue from the same patient, assess the variability of this prevalence among independent specimens within each patient, and examine the biological relationship between mutations whose prevalence is covariant across patients. Which mutations may be useful as early markers of lung cancer in patients with subclinical disease and which may be clinically actionable? How much does the spectrum of known cancer-associated mutations vary between independent premalignant lesions or different samples of the same primary tumor? Are there mutations that are frequently associated with each other or mutually exclusive, and if so, does this covariance reflect the biological relationship of the genes in which they occur?

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

32nd SC Meeting
Thank you to everyone who made the 32nd EDRN Steering Committee meeting a success. The next event is the 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD. More information about this Workshop will be sent soon. Click here to view the flyer.
EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.